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Introduction 
Oxides of nitrogen including nitric oxide (NO) are gases 
present in atmospheric air, and have been considered as 
air pollutants derived predominantly from automobile 
exhaust and domestic gas cookers. Indeed at one stage 
NO was considered as a potential toxic lethal contaminant 
of ‘nitrous oxide cyliders used in anaesthesia (1). How- 
ever, following the independent identification of the 
endothelium-derived relaxing factor (EDRF) by Palmar 
et al. (2) and Ignarro et al. (3) in 1987 as nitric oxide, and 
the subsequent recognition of the L-arginine:NO pathway 
(4,5), NO was named molecule of the year by Science in 
1992. Since then a considerable body of research has been 
conducted to characterize the regulatory role of NO in 
various organ systems in animals and humans, in 
both health and disease, and it is now appreciated that NO 
has a potential involvement in a number of aspects of 
respiratory physiology and pathology. The intention 
of this review is to integrate the recent advances in this 
rapidly growing field. 
Nitric Oxide Metabolism 
SYNTHESIS AND FUNCTION 
NO is synthesized from the semi-essential amino acid 
L-arginine (Fig. 1) in a reaction that involves five-electron 
oxidation of its guanidino nitrogen and is catalysed by a 
family of enzymes called nitric oxide synthases (NOSs) (6). 
This process requires several co-factors including molecular 
oxygen, NADPH, FMN, flavine adenine dinucleotide 
FAD, haem and BH, (7). 
There are now at least three isoforms of NOS which are 
cloned and sequenced (&lo), two being constitutive and 
one inducible (Table 1). The constitutive isoforms (cNOS) 
comprise the endothelial (eNOS) or type III NOS normally 
present in endothelial cells, and the neuronal isoform 
(nNOS) or type I NOS, present in neuronal cells of the 
brain and the peripheral nerves. The constitutive isoforms 
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FIG. 1. Nitric oxide (NO) synthesis by nitric oxide syn- 
thases. Inducible nitric oxide synthase (iNOS) is upregu- 
lated by endotoxins and cytokines, while the constitutive 
counterpart (cNOS) is stimulated by agonists such as 
histamine, acetylcholine and bradykinin. NO synthesis 
involves the conversion of L-arginine to L-citruline in a 
process that requires several co-factors such as molecular 
oxygen (O,), calcium (Ca2’), reduced nicotinamide 
adenine dinucleotide (NADPH), flavine mononucleotide 
(FMN), flavine adenine dinucleotide (FAD), and tetra- 
hydrobiopterine (BH,). 
are calcium dependent and induce transient production of 
picomolar concentrations of NO in response to various 
physiological stimuli, while the inducible isoform (INOS), 
or type II NOS, is upregulated in various cells including 
macrophages, endothelial cells and pulmonary epithelial 
cells in response to stimulation by endotoxins or cytokines, 
such as interferon-y (INF-y), interleukin-lp (IL-ID), and 
tumour necrosis factor a (TNF-a) (11). This isoform gener- 
ates relatively large (nanomolar) concentrations of NO and 
for a more sustained period of time than its constitutive 
counterparts. It is generally thought that iNOS is calcium 
independent. This has, however, been questioned by a 
recent report by Cho et al. (12). These workers identified 
that iNOS contains calmodulin which is tightly bound and 
only requires very low levels of calcium for activation and 
thus gives the impression that it is calcium independent. 
In contrast cNOS binds calmodulin loosely and requires 
much higher cytosolic levels of calcium to produce closer 
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TABLE 1. Nitric oxide synthases (NOS); types and salient features 
Enzyme 
type Isoform 
Gene 
location 
Molecular 
weight (kDa) 
Calcium 
dependent 
Cellular 
site 
neuronal Constitutive Chromosome 150 Yes Cytosolic 
(nNOS) 12 
Type III 
endothelial Constitutive Chromosome 135 Yes Membrane bound 
(eNOS) 7 
Type II 
macrophage Inducible Chromosome 130 ? Cytosolic 
(iNOS) 17 
nNOS, neuronal nitric oxide synthase; eNOS, endothelial nitric oxide synthase; iNOS, inducible 
nitric oxide synthase. 
TABLE 2. Nitric oxide (NO) modulators with their mode of action 
Inhibitors 
NOS inhibitors 
Co-factor 
binding-depletion 
Inhibitors 
of NOS induction 
L-arginine analogues 
L-NMMA, L-NIO 
L-NAME, L-NA 
Guanidines 
Aminoguanidine 
N,N-diaminoguanidine 
1,l -Dimethylguanidine 
Calcium chelators 
Methotrexate 
Glucocorticoids 
Cytokines 
TGF-P, MDF, IL-4, IL-10 
Promotors 
NO adducts NO donors Indirect agonists NOS inducers 
Nitrosated thiols Sodium nitroprusside ACE inhibitors IL-2 
S-nitroso-albumin Nitroglycerine 
S-nitroso-N-acetylcysteine 
NOS, nitric oxide synthase; L-NMMA, p-monomethyl-L-arginine; L-NIO, p-iminoethyl-L- 
ornithine; L-NAME, @-nitro-L-arginine-methyl ester; L-NA, p-L-arginine; TGF-P, transforming 
growth factor p; MDF, macrophage-deactivating factor; IL, interleukin; ACE, angiotensin- 
converting enzyme. 
association with calmodulin, a step necessary for NO 
production. Further support for the dependence of iNOS 
on Ca ‘+ is the identification that calcium chelation 
attenuates the activity of iNOS in human hepatocytes (9). 
NO being a small lipophilic readily diffusible gas is an 
ideal intra- and intercellular messenger. Once it is formed it 
diffuses into the effector cell and binds to the haem iron 
complex of soluble guanylate cyclase (sGC), forming 
nitrosyl-haem that activates guanylate cyclase resulting in 
increased amounts of cyclic guanosine monophosphate 
(cGMP) which leads to activation of the cGMP-dependent 
protein kinase, the mediator of smooth muscle relaxation 
(13). Other functions of NO which are relevant to 
the respiratory system include its inhibitory effect on 
smooth muscle proliferation (14), inhibition of platelet 
aggregation and adhesion (15) and being a neurotrans- 
mitter of bronchodilator nerves in human airways (16) 
together with its cGMP-independent actions which include 
cytotoxic effects due to inhibition of mitochondrial Fees 
enzymes, and cycle-oxygenase activation in macrophages 
(17,18). 
MODULATION OF NO PRODUCTION 
NO Inhibifow 
Interference at any step in the L-arginine:NO pathway can 
lead to inhibition of NO production (Table 2). Binding or 
depletion of the essential co-factors will lead to suppression 
of NO synthesis (7). The guanidino-substituted L-arginine 
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FIG. 2. Schematic representation of the possible routes for nitric oxide (NO) fate. NO may react with 0, forming nitrogen 
dioxide (NO,), dinitrogen trioxide (N203) or dinitrogen tetroxide (N204), and nitrite (NO2 -) is the major end-product of 
this pathway. Secondly, NO may react with superoxide anion (02 -) forming peroxynitrite (OONO -) and peroxynitrous 
acid (OONOH) which are strong oxidizing agents. Thirdly, NO reacts with iron-containing compounds, metalloproteins 
and certain enzymes leading to nitrosylation of these compounds. Finally, through oxidation of NO to higher oxides of 
nitrogen it causes nitrosylation of thiols (RS-NO), or amines (RNH-NO), depending on the concentration of NO. 
analogues are an important group of NOS competitive 
inhibitors commonly used in research. Several analogues 
has been identified such as NC-monomethyl+arginine 
(L-NMMA), fl-nitro+arginine methyl ester (L-NAME), 
and fl-iminoethyl+ornithine (L-NIO). All have the same 
mode of action but vary in potency (19), with L-NIO being 
five times more potent than others, while L-NMMA and 
L-NAME are active orally (20). 
Guanidines are another group of compounds including 
aminoguanidine and N,N-diaminoguanidine which have 
been shown to inhibit NOS. The mechanism whereby these 
compounds exert their inhibitory effect is unknown (21), 
but it is of interest that aminoguanidine appears to be a 
relatively specific inhibitor of iNOS (22). 
Glucocorticoids as well as cytokines, such as members of 
the transforming growth factor p family (TGF-P,, -/?, and 
-$) and macrophage-deactivating factor (MDF), inhibit 
the induction but not the activity of iNOS, although neither 
has any effect on cNOS activity or expression (23,24). 
NO Pvomotevs 
Although nitrates have been used clinically as vasodilators 
for more than a century, it is only recently that their mode 
of action has been realized. It is now appreciated that NO is 
their active intermediate, being generated through the non- 
enzymatic pathway of nitrate metabolism (25). By contrast 
sodium nitroprusside (SNP) releases NO spontaneously 
(26), although a recent report suggested that SNP-induced 
smooth muscle relaxation is probably not mediated by 
cGMP or NO (27). Nitrosylated thiols form a new group of 
compounds known as NO adducts, acting as carrier mol- 
ecules for NO (28) which is released under physiological 
conditions to mediate smooth muscle relaxation. Part of 
the therapeutic effect of angiotensin-converting enzyme 
inhibitors could be linked to their ability to potentiate the 
duration of action of bradykinin, which is a known agonist 
for NO release (29). 
FATE AND TOXICITY OF NO 
Although endogenous NO comes from a single pathway, 
the L-arginine:NO pathway, its fate is more complicated 
and follows several routes (Fig. 2). NO is a free radical and 
its nitrogen atom can exist in multiple oxidative states, 
depending on the conditions of the surrounding micro- 
environment and on the concentration of NO in that 
medium (30,31). The relevance of all these pathways in vivo 
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is uncertain as studies investigating NO metabolites in vitro 
usually use much higher NO concentrations than 
those present under physiological conditions. However, 
notwithstanding these limitations some broad lines can be 
drawn regarding the fate and toxicity of NO. 
Firstly, in oxygenated biological systems, whether aque- 
ous or at air-aqueous interfaces as in the airways, NO 
reacts with oxygen (0,) producing nitrogen dioxide (NO,) 
and other oxidants as intermediates, while nitrite is prob- 
ably the major end-product. The rate of NO, production 
depends on the concentration of NO and oxygen in the 
airways, so under physiological conditions this reaction is 
relatively slow in the gas phase and yields negligible 
amounts of NO,, which is unlikely to affect the biological 
activity of NO (30,31). However, if for any reason signifi- 
cant amounts of intermediates are produced, NO, can lead 
to lipid peroxidation and the other intermediates dinitrogen 
trioxide (N203) and dinitrogen tetroxide (N,O,) can act as 
nitrosylating species (32). Nitrite will remain stable for a 
few hours in aqueous solution, but is rapidly converted in 
the blood to nitrate, which is excreted by the kidneys. 
Nitrates and methaemoglobin form the major end-products 
of the metabolic pathway for endogenously produced 
NO (33). 
Secondly, the lung is a rich source of superoxide anion 
(0 2) which interacts rapidly with NO to produce peroxy- 
nitrite anion (ON00 -) and peroxynitrous acid (OONOH), 
faster than the rate of 0; scavenging by superoxide 
dismutase. It was initially considered that this reaction was 
potentially beneficial, in protecting the lungs from 0 < 
damage (34), but recent reports suggested that ONOO- 
mediates extensive nitrotyrosine formation in lung tissue of 
paediatric patients with acute lung injury (35) and induces 
airway hyperresponsiveness with epithelial damage and 
possible eosinophilic activation in guinea-pigs (36). 
Thirdly, NO has high affinity for iron-containing com- 
pounds such as haem, non-haem metalloproteins and 
certain enzymes (32,37,38). It is through this property that 
NO mediates its biological activity by binding to sGC (13) 
and is also inactivated in the blood through its interaction 
with haemoglobin. This form of interaction can also be 
detrimental, however, as when NO binds to iron-containing 
enzymes such as aconitase and complex I and II of the 
respiratory chain and to ribonucleotide reductase; these 
enzymes become nitrosylated with resultant cytotoxic 
effects, as is evident in activated macrophages (39). 
Finally, through its oxidation to higher oxides of nitro- 
gen, NO can mediate nitrosylation of various compounds 
such as glutathione, cysteine and albumin. The resultant 
,S-nitroso compounds can act as carrier molecules for NO 
or ameliorate the toxicity of the other oxides of nitrogen by 
its combination with 0; (28,32,34). In the presence of high 
concentrations of NO, as in cigarette smoke (40), however, 
nitrosamine formation and deamination may occur and this 
has carcinogenic and genotoxic potential (41). 
MEASUREMENT OF NO 
There are two principal approaches to the measurement of 
NO, direct and indirect methods (42). Direct methods 
depend on trapping of NO by oxyhaemoglobin to form 
nitrosylhaemoglobin adduct which is detected by electron 
paramagnetic resonance, or trapping of NO by reduced 
haemoglobin to form methaemoglobin which is detected by 
spectrophotometry or the reaction of NO with ozone to 
form partially excited NO, and the detection of light 
emission (chemiluminescence) which accompanies cover- 
sion of excited-state to ground-state NO, by a photomulti- 
plier tube. Microelectrode techniques, using amperometric 
means, are another form of direct method with extreme low 
detection thresholds and may be useful in single-cell prep- 
arations (42). However, for clinical measures of NO in 
exhaled air, chemiluminescence is commonly used and is 
very sensitive with a detection threshold of 20 pmol(1 ppb), 
and its specificity has been confirmed (43), although the 
ideal technique for its measurement is still controversial. 
The indirect methods use measurement of cGMP and 
nitrite levels as indicators of NO activity or oxidation 
respectively, while measurement of citrulline, a byproduct 
of the L-arginine:No pathway, has also been used (42). All 
these methods, however, lack specificity. 
Nitric Oxide and the Respiratory System 
Following the discovery of the L-arginine:NO pathway it 
has been proposed that NO is a mediator of biological 
functions in almost all body systems, and the respiratory 
system is no different in this respect, with considerations 
concerning the involvement of NO in normal physiology as 
well as abnormal pathophysiology. 
PRODUCTION SITE 
Although the presence of NO in exhaled air of humans and 
animals has been confirmed (4446) the exact source of its 
production is not yet clear. While some workers (47-52) 
believe that most of the orally exhaled NO in healthy 
subjects is derived from the upper airways, particularly the 
nose or paranasal sinuses (52), others believe that the lower 
airways are the major source of orally exhaled NO at rest 
(53,54) and the contribution of the lower airways is more 
evident during exercise (54). However, all workers agree 
that healthy subjects have significantly higher levels of NO 
in nasally exhaled air than orally exhaled samples, and 
direct measurement of NO in nasal airways still gives much 
higher results. 
The question thus arises as to why the upper airways 
produce such a high concentration of NO and which NOS 
isoform is responsible. One suggested explanation is that 
this relates to bacterial colonization of the nose. Consist- 
ently with this, it has been shown in long-term ventilated 
patients that NO synthesis is reduced by antibiotics (47). 
However, antibiotic therapy in healthy volunteers has no 
effect on exhaled NO (48,51), and the presence of high nasal 
NO in neonates even within the first hour after birth (55) 
makes a bacterial contribution to nasal NO unlikely. Nasal 
biopsy studies have helped to clarify the situation. There is 
evidence that eNOS is expressed in vascular endothelium, 
surface epithelium and submucosal glands of human nasal 
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tissue, while in this study iNOS expression in surface 
epithelium, vascular endothelium and smooth muscle, 
submucosal glands and inflammatory cells was confined to 
those with histological evidence of chronic rhinitis only 
(56). Also, normal nasal mucosal tissue obtained from 
patients undergoing septoplasty contained NOS activity 
which was compatible with a constitutive form and local- 
ized to epithelial cells, whereas nasal polyps, in which there 
is mucosal inflammation, express higher levels of NOS 
activity which is predominantly (80%) inducible in nature 
(57). In support of the constitutive nature of the enzyme 
involved in NO production in the normal nose is the 
observation that topical nasal steroid therapy (budesonide 
4OOpg per nostril daily) has no effect on nasal NO in 
healthy subjects (48). In contradiction to these findings, 
however, other workers have reported that iNOS expres- 
sion is present, albeit at a low level of expression, in the 
epithelium of nasal biopsies from healthy non-atopic indi- 
viduals (58) and that the nasal steroid beclomethasone 
dipropionate, when administered topically at 168,~g per 
nostril daily, significantly reduces nasal NO (51). Recently, 
Lundberg et al. (52), who demonstrated very high levels of 
NO, in the range of 25 ppm, in the paranasal sinus air of 
human subjects, also reported that immunohistochemical 
and in situ hybridization studies revealed a nitric oxide 
synthase resembling iNOS that was constitutively expressed 
in sinus epithelium. In a further report Lundberg et al. (59) 
showed that NOS activity in sinus epithelium is predomi- 
nantly Ca ‘+ independent and not inhibited by high-dose 
systemic steroids (beclomethasone 4-16 mg daily), and they 
concluded that the majority of NO measured in the upper 
airways may be produced in the paranasal sinuses by a 
nNOS isoform which is either identical or very close to 
iNOS. The synthesis of these findings thus suggests that the 
NO measured in nasally exhaled air may reflect NOS 
activity that is both constitutive and inducible and that it is 
derived both from the nasal and paranasal air passages. The 
relevance of the high NO concentration in the upper 
airways remains obscure; it may relate to ciliary function 
(60) in the nasopharynx, antibacterial action in paranasal 
sinuses (52) or conditioning of inspired air in the nasal 
passages (54). 
The source of the lower airway NO production in healthy 
subjects is again incompletely defined. Borland et al. (61) 
suggested that pulmonary vascular endothelium is probably 
the source of exhaled NO, and this suggestion is further 
endorsed by studies on isolated perfused porcine lungs (62); 
however, pulmonary artery embolization in rabbits has no 
effect on exhaled NO levels (44), making the contribution of 
pulmonary vascular endothelium to exhaled NO unlikely. 
Persson et al. (63) suggested that exhaled NO originates 
from the terminal and respiratory bronchioles rather than 
from the alveolar vasculature. Other workers (64), using 
simultaneous recording of exhaled CO, and NO, found that 
NO was elevated throughout the exhalation manoeuvre, 
whereas CO, rises at the end of expiration; furthermore, 
direct sampling of lower airway air at different levels via 
fibre-optic bronchoscopy (53,64) showed similar NO con- 
centrations at various levels, and all these observations 
suggested that NO may be produced throughout the lower 
respiratory tract rather than from the alveoli. Consistent 
with an airway source, both in vitro and in vivo studies 
showed that bronchial epithelial cells have the potential for 
NO production as they express NOS activity , although the 
NOS isoform involved is not consistent in all these studies. 
While some workers have shown that airway epithelial cells 
express iNOS immunoreactivity only after cytokine stimu- 
lation (65), others have shown expression of both nNOS 
and iNOS activity under basal conditions (66), and still 
others have shown that cultured bronchiolar epithelial 
cells, believed to be of Clara cell lineage, express eNOS 
activity (67). 
Analysis of tissue sections has helped clarify the situation 
in humans in vivo. Kobzik et al. (68), using NADPH 
diaphorase reaction and immunostaining with specific anti- 
bodies raised against cNOS and iNOS, identified cNOS 
antigen in human nerves and endothelium only, while the 
epithelium of both human bronchi and rat trachea showed 
uniform labelling with anti-iNOS, suggesting that iNOS 
expression is present in normal airway epithelium. Consist- 
ently with this, a recent in vivo study (69) has demonstrated 
that NO synthesis in normal human airway epithelium is 
due to continuous expression of the iNOS isoenzyme in all 
epithelial cell types, and this expression was found to be 
constant over time and to produce nanomolar levels of NO, 
which were significantly reduced by inhaled steroids and 
rapidly lost following removal of the cells from their in vivo 
environment, suggesting that this tonic expression of iNOS 
is dependent on factors present in the airway milieu. These 
findings endorse another report revealing a low level of 
epithelial iNOS expression in endobronchial biopsies from 
healthy individuals (65). 
From all these observations it seems that all airway 
epithelial cells are capable of producing NO and, although 
conflicting evidence exists as to the exact enzyme isoform 
involved, with some evidence supporting involvement of 
any of the three known isoforms, it is apparent that there is 
a low level of iNOS epithelial expression within normal 
airways. Whether the conflicting in vitro findings are due to 
variability in experimental conditions or whether these 
results relate to a new isoform sharing some characteristics 
with the known ones remains to be elucidated. 
NO AND AIRWAY TONE 
Nitric oxide is a potent relaxant of porcine airway smooth 
muscle in vitro (70), and NOS inhibitors enhance the 
increase in pulmonary resistance induced by intravenous 
histamine in guinea-pigs in vivo (71), indicative of the 
potential for NO to regulate human airway tone. Consist- 
ent with the relevance of airway epithelium to NO synthesis 
and release, NOS inhibitors have been shown to increase 
the basal tone in guinea-pig tracheal tubes with intact 
epithelium, but not in preparations denuded of epithelium. 
Furthermore, bradykinin mediates relaxation in guinea-pig 
tracheal tubes with intact epithelial lining but causes con- 
traction in the presence of NOS inhibitors or in epithelially 
denuded preparations (72), suggesting that NO released 
from epithelial cells can modify the constrictor response to 
bradykinin. This protective effect of NO might be relevant 
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to asthma, a disease in which there is epithelial disrup- 
tion and potentially a loss of this anti-bronchoconstrictor 
protective mechanism. 
The airway effects of NO depend not only on the dose 
administered but also on the state of smooth muscle 
tension. Although low levels of inhaled NO (5 ppm) pro- 
duced a significant reduction of the increased pulmonary 
resistance induced by intravenous methacholine in guinea- 
pigs (73), much higher concentrations of inhaled NO 
(300 ppm) were required to produce a 10% decrease in basal 
airway resistance. Similarly, inhaled NO (100 ppm) has 
been shown to reduce significantly the increase in canine 
airway resistance induced by aerosolized acetylcholine or 
hypocapnia but to have no effect on basal airway resistance 
(74). These protective effects of NO appear to relate to a 
central rather than a peripheral airway effect, as inhalation 
of 80 ppm NO has been shown to protect rabbits effectively 
from the bronchoconstrictor effect of nebulized metha- 
choline (75) but not to ameliorate the induced drop in lung 
compliance. 
Consistent with these animal findings, in humans the 
bronchoconstrictor effect of inhaled bradykinin is greatly 
inhibited by the formation of NO in the airways of asth- 
matic patients (76), and inhaled NO (40-80 ppm) in healthy 
volunteers (77780) and in patients with chronic obstructive 
pulmonary disease (COPD) (7X,80), has no effect on basal 
tone but has a small and inconsistent effect on resting 
airway calibre in asthmatic patients and in healthy subjects 
with hyperreactive airways (78,79,81), in whom there is 
likely to be enhanced basal tone. This effect is much less 
marked than that produced by &adrenoceptor agonists 
and again relates to modulation of central rather than 
peripheral airway tone (81). 
This central effect of NO can be linked to the airway 
distribution of the inhibitory non-adrenergic non- 
cholinergic nerves which are part of the respiratory system 
innervation, as there is evidence of NOS immunoreactivity 
localized to airway neurones in both animals and humans 
(82-84). These neurones are more prominent in proximal 
than distal airways (84). Nitric oxide is considered to be the 
prime neurotransmitter in such (nitrergic) nerves and is 
the mediator of neurally mediated bronchodilatation (16). 
It has been considered that, as diseases like asthma are 
characterized by generalized airway narrowing, there might 
be a defect in the neural nitrergic responses. Studies in vivo 
on resected airway tissue have, however, revealed that the 
nitrergic responses are similar in tissue from both asthmat- 
ics and normal human donors (85). Interestingly the 
nitrergic response to stimulation is markedly reduced in 
airway tissue from cystic fibrosis patients, even though the 
overall NOS activity is generally higher in the presence of 
inflammatory lung diseases (86). 
NO AND PULMONARY VASCULAR TONE 
Vascular endothelial cells produce several vasodilators and 
of these NO and prostacyclin are potentially the most 
important. Although prostacyclin is a powerful vasodilator 
with beneficial effects in primary pulmonary hypertension 
(PPH) (87) it is unlikely that it has a major role in 
maintaining the low resistance of pulmonary circulation 
under physiological conditions (88). This physiological role 
is regulated, at least in part, by endothelially derived NO. 
Pulmonary arterial and venous endothelial cells are 
capable of producing NO (89), and in vitro studies have 
demonstrated that inhibition of the endothelium-dependent 
NO production by NOS inhibitors or by endothelial re- 
moval enhances the response to vasoconstrictor stimuli 
(90,91). In isolated perfused lungs of rabbits (92) and 
humans (93) L-NMMA and methylene blue (a guanylate 
cyclase inhibitor) increases pulmonary vascular resistance, 
and injection of L-NMMA into the pulmonary artery of 
normal humans has been shown to cause a significant 
increase in pulmonary vascular resistance (94). Further- 
more, in healthy conscious adults local infusion of 
L-NMMA into segmental pulmonary arteries resulted in 
a dose-dependent decrease in local flow velocity, while 
acetylcholine infusion resulted in a dose-dependent increase 
in flow velocity (95). All these observations suggest that NO 
is considered the endogenous nitrovasodilator which regu- 
lates the normoxic pulmonary vascular tone under basal 
conditions, and there is evidence that endothelial gener- 
ation of NO is stimulated by physiological stimuli such as 
pulsatile blood flow and shear stress (2). 
Acute hypoxia induces pulmonary vasoconstriction, and 
this pressor response is counteracted by NO release and 
potentiated by NOS inhibitors (93,96). Nitric oxide inhala- 
tion prevents and reverses the hypoxic pulmonary vasocon- 
strictor response in lambs (97) and humans (98). Cremona 
et al. (99) reported low levels of exhaled NO in patients with 
PPH, while Reily et al. (100) in a recent report showed that 
patients with PPH produce normal levels of NO in exhaled 
air at rest, but during exercise the levels failed to rise as in 
normal subjects. These observations are probably related to 
reduced NOS activity, as there is evidence of marked 
reduction in eNOS expression in pulmonary arteries of 
patients with PPH (lOl), and the degree of expression is 
inversely correlated with the total pulmonary resistance. 
Chronic inhibition of NO production in utero has been 
shown to produce persistent pulmonary hypertension in 
new born lambs (102). It is thus evident that NO plays a sig- 
nificant role in the regulation of pulmonary vascular tone. 
Chronic hypoxia is an important cause of pulmonary 
hypertension, and there is evidence that hypoxia markedly 
reduces NOS activity with a decrease in NO release (44). 
Pulmonary arterial rings from patients with COPD have 
marked impairment of endothelial-dependent relaxation in 
response to acetylcholine, with preserved and rather aug- 
mented response to SNP (103) suggesting that COPD 
patients have impaired synthesis or release of NO. Of 
interest therefore is the report that there is only weak eNOS 
immunoreactivity in the pulmonary arteries of patients with 
secondary pulmonary hypertension due to COPD or other 
causes (101). As this disease is characterized by medial 
thickening and intimal proliferation, and as NO has an 
inhibitory effect on vascular mitogenesis and cellular pro- 
liferation (14), it seems likely that the NO deficiency state in 
patients with chronic pulmonary hypertension contributes 
not only to the rise in pulmonary vascular resistance but 
also to the structural vascular changes seen in such patients. 
TOPICAL REVIEW 707 
NO AND PULMONARY GAS EXCHANGE 
The main function of the respiratory tract is gas exchange, 
whereby oxygen and carbon dioxide are transported across 
the alveolar-capillary membranes in opposite directions, to 
maintain normal arterial blood gases. For optimal gas 
exchange ventilation-perfusion (V/Q) matching is a pre- 
requisite. As NO has both vaso- and broncho-dilator 
actions it is probable that the local generation of this 
gas has a role in gas exchange through modulation of 
ventilation and perfusion. 
Some investigators (47,104) believe that autoinhalation 
of NO produced in the upper airways might be implicated 
in ventilation-perfusion matching, as there is evidence that 
aspirated nasal air, in intubated patients, when added to the 
inspiratory limb of the ventilator produces significant fall in 
pulmonary vascular resistance (PVR) and an increase in 
PaO, (104) and low doses of inhaled NO (lo-200 ppb) 
similar to those produced in normal human upper airways 
(105) produce a significant reduction in PVR and improve 
arterial oxygenation in patients with acute respiratory fail- 
ure (106,107). However, the effect of inhaled NO on oxygen 
saturation in healthy volunteers is controversial: while some 
investigators (77,108) demonstrated a significant drop in 
oxygen saturation, which is attributed to alteration in 
perfusion with resultant disturbances in VlQ ratios, other 
investigators using similar doses of inhaled NO have failed 
to find any significant change in arterial oxygen saturation 
(80,98). 
In animal models of adult respiratory distress syndrome 
(ARDS) (109,110) and smoke inhalation injury (11 l), 
inhaled NO improves V/Q matching with significant 
increases in PaO,. In humans inhaled NO reverses acute 
hypoxic pulmonary hypertension without impairment of 
gas exchange (98), and in adults with ARDS (107,112) as 
well as in neonates with severe hypoxaemia not due to 
extrapulmonary shunting (113) inhaled NO improves oxy- 
genation through a significant reduction in shunt fraction 
and improvement in V/Q ratios. The same improvement has 
been demonstrated to occur in children and neonates with 
acute respiratory failure and pulmonary hypertension 
(114,115). Recently, inhaled NO has been found to improve 
arterial oxygenation in high-altitude pulmonary oedema 
(116) probably through redistribution of blood to 
non-oedematous regions, thereby improving V/Q ratios. 
Smokers are known to have lower levels of exhaled NO 
(117,118) and this level is inversely proportional to the 
amount smoked (117). It is thus possible that such an NO 
deficiency state in smokers could contribute to the V/Q 
mismatching seen in many smokers. However, COPD 
patients where shunting is trivial but V/Q mismatching 
is the main cause of hypoxemia (119) studies have 
given conflicting reports as to the value of inhaled NO. 
Administration of NO has been found to produce a 
significant reduction in arterial oxygenation through 
worsening of V/Q ratios (108,120), no change (121) and 
even improvement (122) in oxygenation and gas exchange 
with the use of the same dose of inhaled NO (40 ppm). In 
the absence of consistent findings it is thus unlikely that NO 
will be of therapeutic value in such patients. 
NO AND RESPIRATORY DEFENCE 
MECHANISMS 
For a long time it has been known that resistance to 
infection and cancer can be enhanced in a non-specific way 
by bacterial products (123) and that this resistance can be 
attributed to changes in macrophage behaviour, triggered 
by bacteria of their toxins (124) and inhibited by red blood 
cells or haemoglobin (125). These changes in macrophage 
activity are not due to an alteration in phagocytosis and 
may be either cytostatic or cytotoxic in nature (37). There is 
evidence indicating that NO synthesized by iNOS in acti- 
vated macrophages plays an important role in host defence 
against bacteria, viruses, fungi and parasites as well as its 
role against tumour cells (39). Furthermore, there is also 
evidence that NO inhibits neutrophil adhesion to vessel 
walls (126) and modulates chemotaxis (127). Such diverse 
activities of NO make it indispensable for the immune 
system, and indeed mice lacking the iNOS gene have 
increased susceptibility to infections (128). It is thus poss- 
ible that the relative NO deficiency state in smokers 
(117,118) might contribute to their increased susceptibility 
to infections and tumour growth. In ARDS patients, 
inhaled NO has been found to reduce the activity status of 
neutrophils in addition to reducing IL-8 and IL-6 release 
(129). These effects of NO will tend to ameliorate lung 
inflammation in ARDS. 
The respiratory system is unique in being directly 
exposed to the surrounding environment and acts as an 
immunological filter, so it is probable that the high NO 
concentration in upper airways (45,47-53) reflects a role for 
this gas in mucosal defence mechanisms and that the 
very high levels identified in sinuses by direct puncture 
sampling are involved in maintaining the sterility of this 
environment (52). 
There is also evidence that the L-arginine:NO pathway 
plays a major role in the control of mycobacterial infec- 
tions. Virulent strains of Mycobacterium avium induce NO 
production by human monocyte-derived macrophages 
(130) and it has been demonstrated that killing of myco- 
bacteria by human macrophages is mediated by the 
L-arginine:NO pathway (131). Animal studies have con- 
firmed that an NO-dependent mechanism is important for 
the expression of immunosuppressive activity by macro- 
phages against M avium (132) and that the macrophage 
L-arginine dependent cytotoxic pathway effectively kills 
virulent strains of mycobacteria (133). In support of this, 
NOS inhibitors have deleterious effects on tuberculous 
infection in mice and the severity of mycobacterial infection 
has been shown to be increased in mice lacking the iNOS 
gene (134). Ethanol has been found to attenuate the 
increase in iNOS mRNA and reactive nitrogen metabolites 
in bronchoalveolar lavage fluid induced by instillation of 
mycobacteria into rat lungs (135) suggesting that ethanol 
has an inhibitory effect on alveolar macrophage NO pro- 
duction. In humans alcohol ingestion has been reported to 
result in a significant reduction of exhaled NO in asthmatics 
but not in normal subjects (136) probably reflecting a 
preferential action of alcohol on iNOS which is expressed in 
asthmatic airways. 
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A further important respiratory defence mechanism is the 
mucociliary escalator, and again there is evidence of a 
regulatory role for NO. Nitric oxide upregulates ciliary 
motility in response to stimulation (60) and probably 
mediates the increase in ciliary beat frequency induced by 
,$-agonists (137). The reduced NO production in cigarette 
smokers (117,l IS), with its possible effect on ciliary motil- 
ity, provides an additional possible explanation for there 
increased incidence of respiratory infections. 
However, NO overproduction is not always beneficial, as 
data from animal studies indicate that overproduction of 
NO in acute lung injury is detrimental, particularly in 
association with the production of superoxide anion seen in 
such states, as the resultant peroxynitrite formation may 
lead to oxidative tissue injury (35) and might contribute to 
epithelial damage and airway hyperresponsiveness (36). As 
such, there is evidence implicating NO in the pathogenesis 
of pertusis (138) paraquat lung injury (139), immune- 
complex-mediated lung injury (140) and the hypotensive 
state of septic shock syndrome (141). Also, there is evidence 
that NO may be an important autoregulatory molecule 
preventing the over-expansion of Thl and CD8’ T cells 
(142) but at the same time its overproduction in asthmatics 
may tip the balance in favour of Th2 cells. This effect may 
have a role in perpetuating and amplifying allergic inflam- 
mation through the release of Th2 cytokines, such as IL-4 
and IL-5 with their stimulatory effect on IgE synthesis and 
enhancement of eosinophilic function. Also, it is possible 
that NO overproduction in uncontrolled asthmatics may 
play a central role in epithelial damage seen in such patients 
as it does in pertussis (143). Thus the circumstances and 
magnitude of NO production determine its contribution to 
health or disease. 
NO AS A MARKER OF PULMONARY 
INFLAMMATION 
The low levels of exhaled NO seen in normal subjects 
(4451) are probably produced by constitutive isoforms of 
NOS, while in inflammatory disorders of the respiratory 
tract there is evidence of increased NO production 
following iNOS induction. 
Asthmatic patients have significantly higher levels of 
exhaled NO (45,46,117,144, 145) together with increased 
expression of iNOS in bronchial epithelium (65,146) and 
both NO levels (46,144,145) and iNOS expression (146) are 
reduced by corticosteroid therapy. Acute asthma attacks 
are associated with higher levels of exhaled NO (147), and 
such levels start to fall in 48 h after initiation of cortico- 
steroid therapy, coinciding with the improvement in lung 
function. In stable asthmatics inhaled steroids reduce 
exhaled NO levels (46,144,148) as well as methacholine 
responsiveness before any observed changes in FEV, (144). 
Thus exhaled NO may be a very sensitive index of cortico- 
steroid activity within the airway as changing the dose of 
inhaled steroids leads to changes in exhaled NO well before 
any changes in lung function, symptom scores or &agonist 
use (148). Furthermore, allergen-induced late asthmatic 
reactions are associated with increased levels of exhaled NO 
(149) while early asthmatic reactions (149) as well as acute 
changes in asthmatic airway calibre induced by metha- 
choline and salbutamol have no effect on exhaled NO levels 
(150). All these findings further support to the suggestion 
that exhaled NO is a marker of airway inflammation rather 
than an endogenous modulator of airway tone. At present, 
however, the cost of equipment needed prohibits the 
routine use of exhaled NO levels in daily practice within the 
community. 
Other inflammatory disorders of the respiratory tract are 
also associated with higher production rates of NO; symp- 
tomatic seasonal and perennial rhinitis patients have 
increased levels of exhaled NO (15 l-l 53) and NO metabo- 
lites are increased in nasal lavage fluid from patients with 
house dust mite allergy (154). Increased levels of exhaled 
NO are also reported with viral respiratory tract infections 
(45,155) although this is not a consistent finding (156). In 
bronchiectasis the level of exhaled NO has been found to 
correlate with the extent of the disease, as judged by CT 
scan scores, and bronchiectatic patients not on inhaled 
steroids are reported to have significantly higher levels of 
exhaled NO (157), while children with cystic fibrosis have 
normal levels of orally exhaled NO (158,159) whether or 
not they are on inhaled steroids (158) but have significantly 
lower levels of nasal NO. 
Rejection and graft versus host disease are important 
causes of morbidity and mortality in transplant patients, 
and there is evidence from animal models of transplanta- 
tion indicating that NO production is increased during 
rejection and graft versus host disease (160,161) and that 
urinary nitrite levels rise dramatically during cardiac allo- 
graft rejection in rats (161) before any other sign of 
rejection. As immunosuppressives attenuate urinary nitrite 
levels, NO or its metabolites may form the basis for a 
non-invasive test to detect and monitor rejection in 
transplant patients. 
DIAGNOSTIC AND THERAPEUTIC POTENTIALS 
OF NO 
Although oral L-arginine increases exhaled NO levels in 
asthmatics (162) and inhaled NOS inhibitors reduce it 
(145) there is no evidence that any of these has an effect on 
airway function as measured by FEV,. Direct inhalation of 
NO in asthmatics has a small and inconsistent effect on 
airway function (78,79,81) which is far less significant than 
that of &agonists. The increased NO levels in asthmatics 
are a reflection of the underlying inflammatory process and 
may contribute to the pathogenesis of asthma through 
enhancement of vascular permeability and plasma exuda- 
tion. Consistent with this, inhibition of endogenous NO 
production reduces neurogenic plasma exudation in 
guinea-pig airways (163), and pre-treatment with L-NAME 
suppresses microvascular leakage in sensitized guinea-pig 
airways in a dose-dependent manner (164). Furthermore, 
NOS inhibitors attenuate bradykinin- and histamine- 
induced albumin extravasation in human nasal airways 
(165). In contrast to these reports, however, Gaboury et al. 
(166) demonstrated that an exogenous NO donor reduces 
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microvascular permeability induced by direct activation of 
perivenular mast cells. However, as mentioned earlier, 
measurement of exhaled NO levels in asthmatics could have 
a role in monitoring disease activity and response to 
treatment, and the balance of evidence suggests that 
iNOS inhibition may have beneficial effects on asthmatic 
airways (167). 
In ARDS patients (106,107,112,168), inhaled NO does 
improve oxygenation and haemodynamic variables in most 
patients, with a possible beneficial effect on lung inflam- 
mation through attenuation of the polymorphonuclear 
oxidative burst and adhesion as well as cytokine release in 
the lungs (129). However, so far there is no evidence that 
inhaled NO reduces mortality in ARDS patients (168), 
although it might have an impact on morbidity related to 
oxygen toxicity and barotrauma. Similar responses to 
inhaled NO have also been reported in neonates and 
children with acute respiratory failure and pulmonary 
hypertension due to various causes (113-l 15,169) and 
there is evidence that NO inhalation could obviate the need 
for extracorporeal membrane oxygenation (ECMO) in such 
patients (169). 
In COPD patients (120-122) the hypoxic pulmonary 
vasoconstrictor response limits the disturbance in 
VYQmatching, and through release of this response inhaled 
NO probably worsens oxygenation (120); however, as 
COPD patients have reduced NOS activity (101) with 
impaired NO release, it is possible that exhaled NO in 
COPD patients might predict those who reached the stage 
of chronic respiratory failure requiring long-term oxygen 
therapy. 
In PPH inhaled NO has proven to be a selective and 
specific pulmonary vasodilator (170,17 1) that is superior to 
infused prostacyclin and can predict accurately and safely 
the vasodilator response to calcium channel blockers (172). 
There is a report of one patient with end-stage PPH who 
was maintained on inhaled NO via a transtracheal catheter 
for 68 days until she had a heart-lung transplant (173), and 
her explanted lung showed no evidence of NO toxicity; also, 
a recent report suggested that pulsed delivery of inhaled NO 
through nasal prongs might become an option in the long- 
term treatment of ambulatory patients with PPH (174). 
Post-cardiac-surgery pulmonary hypertension is still an 
important cause of morbidity and mortality, and there is 
good evidence supporting a therapeutic role for inhaled NO 
in such patients (175,176) as well as in patients with 
postoperative graft dysfunction after lung transplantation 
(177). Also, the response to inhaled NO could help in 
discriminating those patients who need heart alone or 
heart-lung transplant (178). 
Finally, studies on pulmonary toxicity of inhaled NO are 
scarce, but the few studies in animals have not revealed 
evidence of toxicity when NO is inhaled for up to 6 months 
(178,179). There is, however, an early human report of 
inhalation of high concentrations of NO (> 1.5%) causing 
severe methaemoglobinaemia with pulmonary oedema and 
death (1). So, as with any other drug, the inhaled NO 
dose has to be tailored to the patient’s needs and the 
minimum effective dose used, with close monitoring of 
methaemoglobin and nitrogen dioxide levels (31). 
Conclusions 
It is thus apparent that NO has the potential to be involved 
in many processes within the respiratory tract and lungs 
and to contribute both to the maintenance of normal 
homeostasis and to the pathogenesis of the disease, depen- 
dent on the nature and extent of its synthesis. With further 
understanding it is hoped that selective modulation or 
enhancement, when appropriate, may lead to novel thera- 
peutic approaches to lung disease and that the measurement 
of NO in exhaled air will provide a valuable marker for 
monitoring airway inflammation in conditions such as 
asthma and rhinitis and assist in the management of 
transplanted patients and possibly also those with COPD. 
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